Increased mortality among patients with acute leukemia admitted on weekends as compared to weekdays
The association between weekend admission and patient outcomes has been reported in several acute illnesses, but is unknown in acute leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 8, 2017 Category: Hematology Authors: Kaushal Parikh, Mahek Shah, Dhruv Mehta, Shilpkumar Arora, Nilay Patel, Delong Liu Source Type: research

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
The FDA approval of ruxolitinib for intermediate and high-risk myelofibrosis in 2011 changed the therapeutic landscape of the disease. We investigated the first-line treatment choices for MF patients in the pre- and post-ruxolitinib eras and found that the increased use of ruxolitinib has come at the expense of several agents, but has not significantly affected the utilization of hydroxyurea in the first-line setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2017 Category: Hematology Authors: Andrew T. Kuykendall, Chetasi Talati, Najla Al Ali, Kendra Sweet, Eric Padron, David A. Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman, Rami S. Komrokji Source Type: research

Generic Imatinib Therapy among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice
This observational study was conducted to assess the efficacy and safety of generic imatinib in 91 patients with chronic myeloid leukemia (either treated first-line or switched from patented to generic imatinib). Efficacy and safety of generic imatinib was comparable to patented imatinib. These results support the use of generic imatinib to reduce healthcare expenditure per patient and increase patient access. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 4, 2017 Category: Hematology Authors: Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid A. Kheirallah Source Type: research

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
We retrospectively evaluated 90 patients with chronic myeloid leukemia receiving either upfront original imatinib (OI) or generic imatinib (GI) for the effect of the early molecular response on the long-term outcome. We demonstrated that achieving an optimal response at 3 and 6 months in patients receiving either first-line GI or OI was clearly associated with greater response and event-free survival rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2017 Category: Hematology Authors: Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafe Tags: Original Study Source Type: research

Outcome of Chronic Myeloid Leukemia Patients with Early Molecular Response at 3 and 6 months: a Comparative Analysis of Generic Imatinib and Glivec
We retrospectively evaluated 90 patients with chronic myeloid leukemia (CML) receiving both upfront original imatinib (OI) and generic imatinib (GI) for the impact of early molecular response on long-term outcome. We demonstrated that achieving optimal response at 3 and 6 months in patients receiving both first-line GI and OI was clearly associated with higher response and event-free survival rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2017 Category: Hematology Authors: Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafe Source Type: research

Philadelphia Chromosome –like Acute Lymphoblastic Leukemia
Philadelphia chromosome –like acute lymphoblastic leukemia (Ph-like ALL) is a recently described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 gene alteration similar to that of Ph-positive ALL. Its prevalence is approximately 12% in children, 21% in adolescents (16-20 years of age), a nd 20% to 24% in adults older than 40 years, with a peak (27%) in young adults 21 to 39 years old. It occurs more often in male individuals and patients with Down syndrome. Ph-like ALL is overrepresented in those with Hispanic ethnicity and is associated with inherited genetic variants in GATA3 (rs3 ...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ching-Hon Pui, Kathryn G. Roberts, Jun J. Yang, Charles G. Mullighan Tags: SOHO State of the Art Updates and Next Questions Source Type: research

New Series: SOHO ‘State of the Art Updates and Next Questions’
It is with great pleasure that the Society of Hematologic Oncology (SOHO) introduces an exciting new article series in this issue of Clinical Lymphoma, Myeloma and Leukemia, the official journal of the society. The new series entitled, “SOHO State of the Art Updates and Next Questions,” is designed to provide readers with: (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Hagop Kantarjian, Moshe Talpaz Tags: Editorial Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Source Type: research

Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia
The treatment of patients with chronic myeloid leukemia in the chronic phase (CML-CP) has changed dramatically in the era of tyrosine kinase inhibitors (TKIs).1 Although most patients will achieve and maintain optimal molecular and cytogenetic responses with TKI therapy, long-term tyrosine kinase inhibition is not without toxicities.2 Cardiovascular events can develop during TKI therapy, mainly in patients with pre-existing cardiovascular disease (CVD) risk factors. Because the life expectancy of patients with CML-CP has increased in this new era, adverse events from TKIs, including CVD, can be challenging for both patient...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ahmet Emre Eskazan Tags: Letter to the Editor Source Type: research

Vascular adverse events under long-term nilotinib therapy in patients with chronic myeloid leukemia
The management of patients with chronic myeloid leukemia in chronic phase (CML-CP) has changed dramatically in the era of tyrosine kinase inhibitor (TKIs) [1]. Although most of the patients achieve and maintain optimal molecular and cytogenetic responses under TKI therapy, long-term tyrosine kinase inhibition in not without toxicities [2]. Cardiovascular events may develop during TKI therapy mainly in patients with preexisting cardiovascular disease (CVD) risk factors. Since the life expectancy of patients with CML-CP had increased in this new era, adverse events (AEs) of the TKIs including CVDs may be challenging for both...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 1, 2017 Category: Hematology Authors: Ahmet Emre Eskazan Tags: Letter to the Editor Source Type: research

Sepsis and Acute Myeloid Leukemia: A  Population-Level Study of Comparative Outcomes of Patients Discharged From Texas Hospitals
We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of> 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-related mortality (30% vs. 21%), with nearly double the hospital length of stay, compared to non-AML patients with sepsis. This information can increase awareness of the risk of sepsis and the need for early intervention in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2017 Category: Hematology Authors: Imrana A. Malik, Marylou Cardenas-Turanzas, Susan Gaeta, Gautum Borthakur, Kristen Price, Jorge Cortes, Joseph L. Nates Tags: Original Study Source Type: research

Sepsis and Acute Myeloid Leukemia: A Population Level Study of Comparative Outcomes of Patients Discharged from Texas Hospitals
We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of> 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-related mortality (30% vs. 21%), with nearly double the hospital length of stay, compared to non-AML patients with sepsis. This information can increase awareness of the risk of sepsis and need for early intervention in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2017 Category: Hematology Authors: Imrana A. Malik, Marylou Cardenas-Turanzas, Susan Gaeta, Gautum Borthakur, Kristen Price, Jorge Cortes, Joseph L. Nates Source Type: research

The clinical spectrum of hepatic manifestations in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world, characterized by the presence of long-lived circulating leukemic cells in the peripheral blood which may infiltrate all organs, particularly those of the reticulo- endothelial system. Liver enlargement and elevation of liver enzymes related to specific involvement by the underlying disease are well-recognized features in these patients. In CLL the differential diagnosis of liver disorders is broad and includes liver infiltration by leukemic cells, immunological manifestations associated with CLL, primary and secondary hepatic malignancies,...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 22, 2017 Category: Hematology Authors: Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor Tags: Review Article Source Type: research

Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review
The treatment landscape for chronic lymphocytic leukemia (CLL) is changing rapidly. Novel targeted agents such as ibrutinib, venetoclax and idelalisib have made a significant impact on both first line, relapsed/refractory, and high-risk disease. Despite these advances, there are continuous needs for new treatment options, especially for patients who fail or cannot tolerate these novel therapies.In 2011, Porter et al reported the first successful use of autologous chimeric antigen receptor T-cells (CART) directed against CD19 in 3 refractory CLL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 20, 2017 Category: Hematology Authors: Anthony R. Mato, Meghan C. Thompson, Chadi Nabhan, Jakub Svoboda, Stephen J. Schuster Tags: Review Article Source Type: research

Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; however, even among those retreated  ≥ 3 years after T1, survival was poor compared with the general population (5-year relative survival = 50%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2017 Category: Hematology Authors: Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles Tags: Original Study Source Type: research

Time to second-line treatment and subsequent relative survival in older patients with relapsed CLL/SLL
We investigated whether stratifying by the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival. Longer time-to-T2 was associated with a modestly improved prognosis; however, even among those retreated ≥3 years after T1, survival was poor compared to the general population (5-year relative survival=50%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2017 Category: Hematology Authors: Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles Source Type: research

Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
The present study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long-term exposure to nilotinib. By considering the effect of cardiovascular risk factors and defining CVEs according to the current 2014 American College of Cardiology/American Heart Association recommendations, the present study attempted to overcome the previous limitations in reporting CVEs in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2017 Category: Hematology Authors: Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim, Diego Hernan Delgado Tags: Original Study Source Type: research

Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long Term Follow up
This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the effect of cardiovascular risk factors and by defining CVEs based on the current 2014 American College of Cardiology/American Heart Association recommendations, this study attempted to overcome the previous limitations in reporting CVEs in CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 15, 2017 Category: Hematology Authors: Nazanin Aghel, Jeffrey Howard Lipton, Eshetu G. Atenafu, Dennis Dong Hwan Kim, Diego Hernan Delgado Source Type: research

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population
Hairy cell leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs (PNAs; Pentostatin/Cladribine). However, treatment is not curative, and subsequent treatment at relapse is often required. Rechallenge with a purine analog is commonly implemented despite limited data regarding the efficacy of this approach. We retrospectively analyzed 61 consecutive patients with HCL diagnosed between 1995 and 2013 at Cleveland Clinic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith, Brian T. Hill Tags: Review Source Type: research

Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Whether to clinically approach follicular lymphoma (FL) grade 3 as an indolent or aggressive lymphoma, especially since the introduction of rituximab, is unclear. Our experience with FL grade 3A, compared with FL grade 3B or with concomitant diffuse large B cell lymphoma, primarily treated with R-CHOP suggests possible long-term remissions. This must be confirmed with longer follow-up and additional studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, Basel Rouphail, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Eric D. Hsi, Mitchell R. Smith Source Type: research

Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. Here we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs observed during treatment with targeted therapies for hematologic and lymphoid malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Julia D. Ransohoff, Bernice Y. Kwong Tags: Review Article Source Type: research

Long Term Outcomes of Hairy Cell Leukemia Treated with Purine Analogs: a Comparison to the General Population
Hairy Cell Leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs [PNAs; Pentostatin/ Cladribine]. However, treatment is not curative and subsequent treatment at relapse is often required. Re-challenge with a purine analog is commonly implemented despite limited data regarding the efficacy of this approach. We retrospectively analyzed 61 consecutive HCL patients diagnosed between 1995 and 2013 at Cleveland Clinic. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 13, 2017 Category: Hematology Authors: Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith, Brian T. Hill Source Type: research

Characteristics of vitamin B12 deficiency in patients with plasma cell disorders
Vitamin B12 deficiency is prevalent among patients with plasma cell dyscrasias (PCDs) but the association is poorly understood. Among 501 patients with PCDs, 20% had low B12. Low B12 was more prevalent in patients with preserved renal function. MCV was not clinically different between low and normal B12 patients and may not be reliable in PCDs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 11, 2017 Category: Hematology Authors: Caitlyn Braschi, John Doucette, Ajai Chari Tags: Original Study Source Type: research

What is the role of chemotherapy in patients with chronic lymphocytic leukemia?
The current standard treatment for patients with chronic lymphocytic leukemia (CLL) who require therapy is chemoimmunotherapy. However, the availability of an increasing number of targeted agents and combination warrants a reassessment of that approach. The high rate of durable responses with ibrutinib in relapsed refractory patients has established its role in this setting; however, because of its impressive efficacy as initial treatment, it should be considered as part of the algorithm in appropriate patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 11, 2017 Category: Hematology Authors: Bruce D. Cheson Tags: Review Article Source Type: research

Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction
The Total Neuropathy Score is ideal for evaluation of bortezomib-induced neuropathy. We used the reduced (TNSr) and clinical (TNSc) forms as well as the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 to assess incidence of neuropathy in patients receiving cyclophosphamide, bortezomib, and dexamethasone as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40%, and 45% developed neuropathy when assessed by TNSr, TNSc, and NCI CTCAE, respectively. We found wide variation in TNSr and TNSc even when the NCI CTCAE scale reported no progression of neuropathy. (Source: Cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Arjun Lakshman, Manish Modi, Gaurav Prakash, Pankaj Malhotra, Alka Khadwal, Sanjay Jain, Savita Kumari, Neelam Varma, Subhash Varma Tags: Original Study Source Type: research

Evaluation of bortezomib induced neuropathy using Total Neuropathy Score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction
Total Neuropathy Score (TNS) (reduced and clinical versions) is ideal for evaluation of bortezomib induced neuropathy. We used TNSr and TNSc along with NCI CTCAE v4.0 to assess incidence of neuropathy in patients receiving CyBorD as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40% and 45% developed neuropathy when assessed by TNSr, TNSc and NCI CTCAE respectively. We found wide variation in TNSr and TNSc even when NCI CTCAE scale reported no progression of neuropathy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Arjun Lakshman, Manish Modi, Gaurav Prakash, Pankaj Malhotra, Alka Khadwal, Sanjay Jain, Savita Kumari, Neelam Varma, Subhash Varma Tags: Original Study Source Type: research

Acute Promyelocytic Leukemia: A perspective
With increased understanding of the mechanisms of carcinogenesis and the dissection of complex, aberrant cellular pathways that underlie neoplastic transformation, it is becoming more clear that diseases once considered morphologically similar are clearly diverse and require specific strategies to achieve response and potentially long term cure. Attacking specific pathways that drive a given cancer exemplifies the precison medicine approach nowhere better characterized than in acute myeloid leukemia (AML) where identification othe characterization ofmolecular aberrations is already leading to the development of novel and m...
Source: Clinical Lymphoma, Myeloma and Leukemia - July 5, 2017 Category: Hematology Authors: Farhad Ravandi, Richard Stone Tags: Perspective Source Type: research

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
An independent dataset of 91 multiple myeloma patients were tested with eight prognostic mRNA expression signatures. SKY92 best predicted survival (HR = 8.2) and classified the largest fraction (21%) as high risk. Finally 38/91 (42%) cases were low risk by the recently proposed combination SKY92 + ISS achieving a HR 10 for low versus high risk. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2017 Category: Hematology Authors: Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keit Tags: Original Study Source Type: research

Prognostic validation of SKY92 and its combination with ISS in an independent cohort of Multiple Myeloma patients
Multiple myeloma (MM) is a genetically heterogeneous disease with associated heterogeneous outcomes.[1,2,3,4] In recent years, high risk disease emerged as one of the challenging and unmet needs in the treatment of MM. A number of ongoing and planned studies attempted to develop risk stratified approaches to improve outcomes of high risk MM. To make progress in this area, it is important to accurately and meaningfully identify high risk and low risk MM patients. A number of biomarkers have been proposed to define and elucidate this heterogeneity including genetic and biochemical parameters. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 3, 2017 Category: Hematology Authors: Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keit Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - July 1, 2017 Category: Hematology Source Type: research

Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome
We report on a case of HSOS after vincristine administration that was successfully treated with defibrotide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Catherine Tang, Julian Lindsay, Anthony Gill, Ian Kerridge Tags: Case Report Source Type: research

Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies
Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Mara Penne, Maryam Sarraf Yazdy, Kruti Sheth Nair, Bruce D. Cheson Tags: Original Study Source Type: research

Extended Follow up of Patients Treated with Bendamustine for Lymphoid Malignancies
Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Mara Penne, Maryam Sarraf Yazdy, Kruti Sheth Nair, Bruce D. Cheson Tags: Original Study Source Type: research

Proteasome Subunit Beta Type 1 P11A polymorphism is a new prognostic marker in multiple myeloma
We retrospectively analyzed the prognostic impact of Proteasome subunit beta type 1 rs12717 polymorphism in 211 consecutively diagnosed multiple myeloma cases. Patients carrying the variant G allele showed significantly shorter progression free survival. In proteasomes of individuals with G/G genotype we found significantly reduced protease activity and lower inhibitory capacity of bortezomib on the caspase- and trypsin-like activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Gergely Varga, G ábor Mikala, Katalin Piroska Kiss, Éva Kosóczki, Edit Szabó, Nóra Meggyesi, Katalin Balassa, Petra Kövy, Bálint Tegze, Gergely Szombath, Attila Tordai, Hajnalka Andrikovics, László Homolya, Tamás Masszi Tags: Original Study Source Type: research

Defibrotide use in vincristine induced hepatic sinusoidal obstruction syndrome
We report on a case of HSOS after vincristine administration that was successfully treated with defibrotide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 30, 2017 Category: Hematology Authors: Catherine Tang, Julian Lindsay, Anthony Gill, Ian Kerridge Tags: Case Report Source Type: research

How to Approach a Patient with Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?
The use of 18 F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET may even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET positive after chemotherapy is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 29, 2017 Category: Hematology Authors: Nmazuo W. Ozuah, Ann S. LaCasce Tags: Review Article Source Type: research

The role of low-dose anti-thymocyte globulin as standard prophylaxis in mismatched and matched unrelated hematopoietic peripheral stem cell transplantation for hematologic malignancies
Anti-thymocyte globulin (ATG) - based immunosuppressive therapy is often used in allogeneic hematopoietic cell transplantation (alloHCT) to reduce incidence and severity of graft-vs-host disease (GVHD). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 28, 2017 Category: Hematology Authors: Ioanna Sakellari, Ioannis Batsis, Zoi Bousiou, Despina Mallouri, Varnavas Constantinou, Eleni Gavriilaki, Christos Smias, Evangelia Yannaki, Panayotis Kaloyannidis, Giorgos Papaioannou, Niki Stavroyianni, Antonia Syrigou, Damianos Sotiropoulos, Asimina Fy Tags: Original Study Source Type: research

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study
In a retrospective study of 309 patients with myelofibrosis (MF), severe burden of comorbidities as assessed by the Adult Comorbidity Evaluation 27 (ACE-27) or Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) was associated with worse overall survival. ACE-27 may be preferred for comorbidity assessment in myeloproliferative neoplasm (MPN) patients as it captures cardiovascular and venous thrombosis related morbidities better than HCT-CI. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 28, 2017 Category: Hematology Authors: Justyna Bartoszko, Tony Panzarella, Caroline Jane McNamara, Anthea Lau, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Dawn Maze, Karen W.L. Yee, Rebecca Devlin, Vikas Gupta Tags: Original Study Source Type: research

Effectiveness of single-dose rasburicase in patients with lymphoid malignancies at a high risk for tumor lysis syndrome
Tumor lysis syndrome (TLS) is a life-threatening disorder that occurs mainly in patients with high-tumor burden hemato-oncologic malignancies. It results in metabolic derangements, including hyperuricemia and acute renal failure. The powerful management for TLS is a daily dose of rasburicase for up to five days before chemotherapy; however, the optimal dose and duration of rasburicase for TLS prophylaxis have not been standardized for patients at high risk for TLS. Therefore, we evaluated the efficacy of single-dose rasburicase for prophylactic purposes in patients with malignant lymphoma at high risk for TLS. (Source: Cli...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2017 Category: Hematology Authors: Young-Woo Jeon, Dae-Hun Kwak, Sung-Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Jong Wook Lee, Woo-Sung Min, Seok-Goo Cho Tags: Original Study Source Type: research

Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
In 2015, two monoclonal antibodies were approved for the treatment of relapsed or refractory multiple myeloma (RRMM), elotuzumab and daratumumab. Elotuzumab is a monoclonal IgG- κ antibody directed against SLAMF7, a cell surface receptor involved in natural killer cell activation. Daratumumab is a monoclonal IgG-κ antibody that binds to CD38, a transmembrane protein found on the surface of myeloma cells responsible for cellular adhesion and ectoenzymatic activity. Both el otuzumab and daratumumab act through recruitment of the immune system to enhance cellular cytotoxicity directed against myeloma cells. (Sourc...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 26, 2017 Category: Hematology Authors: Daniel W. Sherbenou, Tomer M. Mark, Peter Forsberg Tags: Review Article Source Type: research

Extrafollicular PD1 and Intrafollicular CD3 Expression Are Associated With Survival in Follicular Lymphoma
This study aimed to stratify follicular lymphoma (FL) patients' outcome according to immunohistochemical parameters. The study correlated Ki-67, CD68, PD1 and CD3 results with clinical outcome. We found that high extrafollicular PD1 and low intrafollicular CD3 correlated with better outcome. Further studies are necessary in order to understand the complexity of the tumor microenvironment and its association with FL outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Kedmi Meirav, Schiby Ginette, Tadmor Tamar, Barshack Iris, Nagler Arnon, Avigdor Abraham Tags: Original Study Source Type: research

Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
The present study investigated the outcomes in different age groups of 101 patients receiving front-line imatinib therapy for chronic myeloid leukemia. Middle-age patients had a significantly greater rate of major molecular response, a superior estimated 6-year event-free survival, and a greater estimated 6-year overall survival rate compared with younger and elderly patients and, consequently, the best long-term treatment outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Irena Ćojbašić, Lana Mačukanović-Golubović, Miodrag Vučić, Ivan Tijanić Tags: Original Study Source Type: research

Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients with Myelodysplastic Syndromes from the Argentine Database
In our retrospective review of 831 patients, 158 progressed with a very poor outcome (median survival after evolution: 3.5 months). The survival of patients with adverse karyotypes or with higher IPSS-R or WPSS risk was not affected upon comparison of patients with or without evolution to AML. Our results may help individualizing those patients that would require a more aggressive treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Alicia Enrico, Yesica Bestach, Maria Gabriela Flores, Jorge Arbelbide, Camila Serale, Viviana Novoa, Ren ée Crisp, María Marta Rivas, Irene Larripa, Carolina Belli Tags: Original Study Source Type: research

Extrafollicular PD-1 and intrafollicular CD3 expression are associated with Survival in follicular lymphoma
Both microenvironment and tumor biomarkers impact outcome in follicular lymphoma (FL). We aimed to study the effect of Ki-67, CD3, CD68 and PD-1 expression on outcome of FL. Forty eight patients were included. Stained slides were visually assessed and markers expression was correlated with outcome.Both intra and extra-follicular expression of Ki-67, CD68 and PD-1 were evaluated. CD3 was evaluated only in the intra follicular area. The median values of expression served as a cutoff point for low and high expression groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Kedmi Meirav, Schiby Ginette, Tadmor Tamar, Barshack Iris, Nagler Arnon, Avigdor Abraham Tags: Original Study Source Type: research

Risk of Second Primary Malignancies in Patients with Follicular Lymphoma: A United States population-based study
Follicular Lymphoma (FL) is a common low grade lymphoma with excellent long term survival in the present era. We utilized the Surveillance, Epidemiology and End Results (SEER) registry to identify patients with Follicular Lymphoma from 1992-2010 and study the incidence and risk factors for the development of Second Primary Malignancies (SPM). During a median follow up of 71 months, 1540 patients (9.9%) developed SPM, with a cumulative incidence of 11% at 10 years and an increased risk of both hematological as well as solid malignancies. This risk was significantly increased among patients>65 years, male and those receiv...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Smith Giri, Vijaya Raj Bhatt, Vivek Verma, Ranjan Pathak, R. Gregory Bociek, Julie M. Vose, James O. Armitage Tags: Original Study Source Type: research

Precision medicine in myeloma: Challenges in defining an actionable approach
Recently, large sequencing studies have provided insights into the mutational landscape of multiple myeloma (MM), identifying actionable mutations and giving a precious opportunity for exploring new targeted therapies. The main goal of precision medicine, matching patients with the right drug, seems to be closer than ever. However, no targeted therapies in MM are approved yet. Several clinical trials testing targeted drugs and enrolling MM patients are currently ongoing and will provide predictive biomarkers that might support clinical decision-making. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Ver ónica González-Calle, Niamh Keane, Esteban Braggio, Rafael Fonseca Tags: Review Article Source Type: research

Analyses of treatment outcome according to age in patients with chronic myeloid leukemia receiving imatinib frontline
This study investigates outcome in different age groups of 101 imatinib frontline treated patients with chronic myeloid leukemia. Middle aged patients had a significantly higher rate of major molecular response, superior estimated 6-year event-free survival and higher rate of the estimated 6-year overall survival compared to younger and elderly patients, and consequently the best long-term treatment outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: I. Ćojbašić, L. Mačukanović-Golubović, M. Vučić, I. Tijanić Tags: Original Study Source Type: research

Smoldering Multiple Myeloma: Who and when to treat
Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell disorder characterized by the presence of ≥ 3 g/dL serum M-protein and/or 10-60% bone marrow plasma cell infiltration with no myeloma-defining event. The risk of progression to active MM is not uniform, and several markers are useful for identifying patients at high risk of progression. The definition of the disease has recently been revi sited and asymptomatic MMs at 80-90% of progression risk at 2 years are now considered to be active MMs candidates for treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 24, 2017 Category: Hematology Authors: Mar ía-Victoria Mateos, Verónica González-Calle Tags: Review Article Source Type: research